Arctic Bioscience — Regulatory Filings 2022

Jun 13, 2022

Arctic Bioscience - New and extended agreement with Kotler Marketing Group to strengthen position in the Chinese market

Arctic Bioscience - New and extended agreement with Kotler Marketing Group to strengthen position in the Chinese market

Arctic Bioscience, a biotech company developing and commercializing

nutraceutical and pharmaceutical products based on the unique properties of

bioactive marine compounds, has signed a new and extended strategic partnership

agreement with Tromso Nutrition Technologies Co. LTD, a subsidiary of Kotler

Marketing Group China. This new agreement expands the already existing

cooperation between the parties through 2025.

"We are very happy to continue our partnership with Kotler Marketing Group in

China and the extension reinforces the commitment between the two companies. The

expansion of the partnership opens for access to an even larger part of the

Chinese market, consolidating and strengthening our growth ambitions in the

region", CEO of Arctic Bioscience, Christer L. Valderhaug, comments.

The scope of business focus is development of the nutraceutical business in

China. The extension of the agreement also includes potential collaboration

within the Pharma space, where Arctic Bioscience has several interesting

products under development, including the HRO350 for treatment of mild to

moderate psoriasis and a novel drug candidate for brain development in extremely

premature infants.

"This agreement will further support Arctic Bioscience in product development,

marketing strategies and supply chain optimization, as well as strengthening the

cross over between our nutraceutical business and our pharmaceutical ambitions",

Valderhaug comments.

Increased order intake from the Chinese market

Based on the existing agreement with Kotler Marketing Group, Arctic Bioscience

has received order intake more than double the size than forecasted for this

fiscal year related to the Chinese market.

"We are very pleased with the development we see for our operations and business

in China", says Valderhaug. "Going forward we are positive that the extended

partnership agreement will give us a stronger market position and increased

sales of our nutraceutical products in the Chinese market," Valderhaug ends.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel investigational drug candidate.

HRO350 is being developed for treatment of patients with mild-to-moderate

psoriasis. This is a large patient group in need of new effective medicines with

beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.